Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness

Medical Decision Making

Volumn 29, Issue 5, 2009, Pages 557-569

  Bauch, Chris T ^a   Anonychuk, Andrea M ^b,c   Van Effelterre, Thierry ^d   Pham, Ba Z ^c   Merid, Maraki Fikre ^c  

^a UNIVERSITY OF GUELPH   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Cohort model; Cost effectiveness analysis; Decision modeling; Dynamic model; Herd immunity; Universal vaccination

Indexed keywords

CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; VACCINES;

EID: 72849128187     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X09334419     Document Type: Article

References (26)

1. Tucker A., Haddix A., Bresee J., Holman R., Parashar U., Glass R. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998 ; 279: 1371-1376.
2. Lee G., Murphy T., Lett S., et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med. 2007 ; 32 (3). 186-193.
3. Shepard C., Ortega-Sanchez I., Douglas S., Rosenstein N. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005 ; 115 (5). 1220-1232.
4. Krahn M., John-Baptiste A., Qilong Y., et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high-risk and average-risk populations in Canada. Vaccine. 2005 ; 23 (13). 1549-1558.
5. Goldie SJ, Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004 ; 96 (8). 604-615.
6. Kulasingam SL, Myers ER Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003 ; 290 (6). 781-789.
7. Edmunds W., Medley G., Nokes D. Evaluating the cost-effectiveness of vaccination programs: a dynamic perspective. Stat Med. 1999 ; 18 (23). 3263-3282.
8. Brisson M., Edmunds W. Economic evaluation of vaccination programs: the impact of herd immunity. Med Decis Making. 2003 ; 23 (1). 76-82.
9. Garnett GP Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005 ; 191: S97 - S106.
10. Bauch CT, Anonychuk AM, Pham BZ, Gilca V., Duval B., Krahn MD Cost-utility of universal hepatitis A vaccination in Canada. Vaccine. 2007 ; 25 (51). 8536-8548. (Pubitemid 350192045)
11. Dasbach E., Elbasha E., Insinga R. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and diseases. Epidemiol Rev. 2006 ; 28 (1). 88-100.
12. Bauch C., Anonychuk A., Pham B. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine. 2007 ; 25 (51). 8536-8548. (Pubitemid 350192045)
13. Newall A., Beutels P., Wood J., Edmunds W., MacIntyre C. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet. 2007 ; 7 (4). 289-296.
14. Diel R., Rappenhoener B., Schneider S. Cost-effectiveness of hepatitis A immunization of children and adolescents in Germany. Health Econ Prev Care. 2001 ; 2: 96-103.
15. Beutels P., Gay N. Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country. Epidemiol Infect. 2003 ; 130: 273-283.
16. Trotter C., Edmunds W. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making. 2006 ; 26 (1). 38-47.
17. Elbasha EH, Dasbach EJ, Insinga RP Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007 ; 13 (1). 28-41.
18. Taira A., Neukermans C., Sanders G. Evaluating human papillomavirus programmes. Emerg Infect Dis. 2004 ; 10 (11). 1915-1923.
19. Edwards D., Schachter R., Owens D. A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs. Interfaces. 1998 ; 28 (3). 144-166.
20. Anderson R., May R. Infectious Diseases of Humans. Oxford (UK): Oxford University Press ; 1991.
21. Barnabas RV, Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006 ; 3 (5). 624-632.
22. Lexau C., Lynfield R., Pilishvili T., Facklam R., Farley M. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005 ; 294 (16). 2043-2051.
23. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine. 2007 ; 25: 1355-1367.
24. Whitney C., Farley M., Hadler J., Harrison L., Bennett N., Lynfield R. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003 ; 348 (18). 1737-1746. (Pubitemid 36514704)
25. Haber M., Barskey A., Baughman W., et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007 ; 25: 5390-5398.
26. Bauch C., Earn D. Transients and attractors in epidemics. Proc R Soc Lond B. 2003 ; 270: 1573-1578.